TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00971516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: dental implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants surgery
Description: dental implant surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants surgery
Description: dental implant surgery
Study: NCT00253903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT01429714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individually tailored duration of elastic compression therapy
Description: Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic compression therapy with a standard duration of 24 months
Description: Elastic compression therapy with a standard duration of 24 months
Study: NCT01055106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: vaginal gel 0.75% once daily for 5 days
Study: NCT03748537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
Study: NCT01355783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7777
Description: Treatment in both arms is for 6 cycles at 21 days/cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7777
Description: Treatment in both arms is for 6 cycles at 21 days/cycle.
Study: NCT03285009

Intervention type: OTHER
Group type: OTHER
Intervention: Training intervention
Description: Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school.
Study: NCT04356105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minimal stimulation protocol
Description: Letrozole, Recombinant FSH, GnRH antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microflare protocol
Description: OCP, GnRH agonist, Recombinant FSH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI cycle
Description: Involving ovum pickup and embryo transfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI cycle
Description: Involving ovum pickup and embryo transfer
Study: NCT01674543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
Study: NCT02288975

Intervention type: DEVICE
Intervention: CytoSorb 300ml device (3804606CE01)
Study: NCT01992198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefoperazone + metronidazole
Description: 1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral care by chlorhexidine gluconate
Description: oral care by 0.2% chlorhexidine gluconate twice daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral care by chlorhexidine gluconate
Description: oral care by 0.2% chlorhexidine gluconate twice daily
Study: NCT03174743

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Convential Ventilation 1
Description: High tidal volume, moderate inspired oygen fraction (FiO2).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Convential Ventilation 2
Description: High tidal volume, high inspired oygen fraction (FiO2).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective Ventilation 1
Description: Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective Ventilation 2
Description: Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
Study: NCT02353078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Sucralfate slurry 1 gram four times daily for four weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraluminal Impedance
Description: During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraluminal Impedance
Description: The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
Study: NCT05090540

Intervention type: DEVICE
Intervention: Trancatheter Edge to Edge Repair
Description: TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation

Intervention type: PROCEDURE
Intervention: Mitral Valve Replacement
Description: Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.

Intervention type: PROCEDURE
Intervention: Restrictive Mitral Annuloplastie
Description: Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring

Intervention type: PROCEDURE
Intervention: Restrictive Mitral Annuloplastie/Subvalvular Repair
Description: RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
Study: NCT01992198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enteral nutrition

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutrition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h
Study: NCT00972985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: oral tablet, 100 mg, single acute dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: oral tablet, 20 mg, single acute dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorazepam
Description: oral tablet, 1 mg, single, acute dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet, single acute dose
Study: NCT00989170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Program for the Prevention of Weight Gain
Description: The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
Study: NCT04624633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral, twice a day, predetermined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral, twice a day, predetermined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: 28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: 28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
Study: NCT01601392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (Anodal)
Description: The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (Cathodal)
Description: The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (Sham)
Description: The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
Study: NCT02659345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions Thermometer
Description: The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
Study: NCT03229746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg twice daily orally for at least 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1mg intravenous weekly for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: dose 100mg daily for at least 3 weeks
Study: NCT01842893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Ethypharm
Description: After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
Study: NCT00069953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
Study: NCT01063881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
Study: NCT01309100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens
Description: Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Lens
Description: Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua Lens
Description: Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
Study: NCT00197873

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus supplementation
Description: Lactophilus supplementation is administered during chemotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Rhamnosus supplementation
Description: Lactophilus supplementation is administered during chemotherapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration.
Description: Placebo is administered during chemotherapy.
Study: NCT02452619

Intervention type: OTHER
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy
Study: NCT02290262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive phase one rehabilitation
Description: Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse.
Study: NCT02663349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Intervention Training
Description: A manualized group therapy that teaches social cognitive skills.
Study: NCT02923336

Intervention type: DRUG
Group type: OTHER
Intervention: non selective beta blocker
Description: the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time
Study: NCT02096705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin Placebo
Description: Tablet
Study: NCT03669731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food diary
Description: This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food diary
Description: This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food diary
Description: This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
Study: NCT01328782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone with Acetaminophen
Description: 0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: * Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.20%
Description: * Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg
Study: NCT04224584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will act as a control for duloxetine.
Study: NCT03946436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active video games
Description: Participants played the active video game Virtua tennis 4 on a playstation kinect device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tennis training process
Description: Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tennis training process
Description: Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.